Glycoforms | Cancer stage | Patients’ survival | ||||
---|---|---|---|---|---|---|
Early | Advanced | P | Top 25% percentile of survival | Ordinary | P | |
Galactosylation of IgG1 (%) | 61.66 ± 5.26 | 58.02 ± 4.07 | 0.007* | 59.67 ± 4.16 | 57.93 ± 4.29 | 0.060 |
Agalactosylation of IgG1 (%) | 17.38 ± 4.54 | 20.24 ± 4.42 | 0.044* | 19.24 ± 4.31 | 20.21 ± 4.55 | 0.317 |
Bisected glycoforms of IgG1 (%) | 29.58 ± 6.42 | 31.81 ± 5.71 | 0.226 | 30.21 ± 5.35 | 32.06 ± 5.89 | 0.140 |
Sialylation of IgG1 (%) | 16.97 ± 5.47 | 17.54 ± 4.13 | 0.673 | 17.61 ± 4.22 | 17.44 ± 4.29 | 0.853 |
Fucosylated of IgG1 (%) | 79.40 ± 6.32 | 81.17 ± 4.17 | 0.208 | 79.50 ± 3.97 | 81.50 ± 4.46 | 0.034* |
Agalactosylation ratio | ||||||
 Agalactosylation ratio of IgG1 | 0.93 ± 0.30 | 1.10 ± 0.62 | 0.371 | 0.10 ± 0.38 | 1.12 ± 0.65 | 0.351 |
 Agalactosylation ratio of IgG2 | 1.01 ± 0.35 | 1.05 ± 0.48 | 0.789 | 1.01 ± 0.40 | 0.06 ± 0.49 | 0.651 |
 Agalactosylation ratio of IgG4 | 1.08 ± 0.49 | 1.46 ± 0.80 | 0.090 | 1.34 ± 0.53 | 1.49 ± 0.85 | 0.370 |
Sialylation ratio | ||||||
 Sialylation ratio of IgG1 | 0.55 ± 0.17 | 0.58 ± 0.33 | 0.764 | 0.49 ± 0.24 | 0.60 ± 0.33 | 0.080 |
 Sialylation ratio of IgG2 | 0.42 ± 0.22 | 0.41 ± 0.20 | 0.865 | 0.35 ± 0.18 | 0.43 ± 0.20 | 0.053 |
 Sialylation ratio of IgG4 | 0.81 ± 0.39 | 0.66 ± 0.42 | 0.277 | 0.71 ± 0.48 | 0.66 ± 0.39 | 0.641 |
Summation | ||||||
 Agalactosylation ratio of IgG1 and agalactosylation ratio of IgG4 | 2.07 ± 0.25 | 2.50 ± 0.12 | 0.026* | 2.51 ± 0.18 | 2.44 ± 0.14 | 0.782 |
 Sialylation ratio of IgG2 and sialylation ratio of IgG4 | 1.57 ± 0.26 | 1.97 ± 0.11 | 0.025* | 1.76 ± 0.18 | 1.99 ± 0.12 | 0.322 |
 Sialylation ratio of IgG1, sialylation ratio of IgG2, and sialylation ratio of IgG4 | 2.28 ± 0.33 | 2.75 ± 0.14 | 0.030* | 2.49 ± 0.23 | 2.77 ± 0.16 | 0.359 |